Verici Dx plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRCI.L research report →
Companywww.vericidx.com
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure.
- CEO
- Sara jane Barrington
- IPO
- 2020
- Employees
- 19
- HQ
- Penarth, GB
Price Chart
Valuation
- Market Cap
- $6.05M
- P/E
- -0.19
- P/S
- 5.50
- P/B
- 0.52
- EV/EBITDA
- -1.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 105.81%
- Op Margin
- -472.64%
- Net Margin
- -468.31%
- ROE
- -178.37%
- ROIC
- -243.15%
Growth & Income
- Revenue
- $3.34M · 229.62%
- Net Income
- $-5,874,000 · 32.75%
- EPS
- $-0.03 · 50.88%
- Op Income
- $-6,106,000
- FCF YoY
- 15.94%
Performance & Tape
- 52W High
- $1.75
- 52W Low
- $0.40
- 50D MA
- $0.50
- 200D MA
- $0.64
- Beta
- 1.30
- Avg Volume
- 1.36M
Get TickerSpark's AI analysis on VRCI.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VRCI.L Coverage
We haven't published any research on VRCI.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VRCI.L Report →